文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除标本中伴发原位癌的预后价值:系统综述与meta分析

Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2019-01-01

该系统综述与meta分析纳入23项研究共20647例根治性膀胱切除患者,评估标本中伴发原位癌的预后价值。总体人群中伴发原位癌与总死亡率、无复发生存率及癌症特异性死亡率无关,但与输尿管受累相关;在器官局限患者中伴发原位癌与更差的无复发生存率和癌症特异性死亡率相关。

要点

  • 根治性膀胱切除标本中伴发原位癌总体与总死亡率、无复发生存率及癌症特异性死亡率无关。
  • 伴发原位癌与输尿管受累显著相关( pooled OR 4.51,2.59-7.84)。
  • 器官局限患者中伴发原位癌与更差的无复发生存率(HR 1.57,1.12-2.21)和癌症特异性死亡率(HR 1.51,1.001-2.280)相关。

核心结论

  • 伴发原位癌与根治性膀胱切除患者的输尿管受累显著相关。
  • 在器官局限患者中,伴发原位癌是无复发生存率和癌症特异性死亡率的预后因素。

研究设计与样本

  • 系统综述与meta分析,检索MEDLINE、Scopus、Web of Science和Cochrane Library至2017年10月。
  • 纳入23项研究共20647例根治性膀胱切除患者,方案注册于PROSPERO(CRD42018086539)。

主要发现

  • 伴发原位癌在根治性膀胱切除标本中报告率为39.4%。
  • 总体人群中伴发原位癌与总死亡率( pooled HR 0.92,0.77-1.10)无关。
  • 总体人群中伴发原位癌与无复发生存率( pooled HR 1.06,0.99-1.13)无关。
  • 总体人群中伴发原位癌与癌症特异性死亡率( pooled HR 1.00,0.93-1.07)无关。
  • 伴发原位癌与输尿管受累相关( pooled OR 4.51,2.59-7.84)。

关键数值与推荐

  • 器官局限患者中伴发原位癌与更差的无复发生存率相关( pooled HR 1.57,1.12-2.21)。
  • 器官局限患者中伴发原位癌与更差的癌症特异性死亡率相关( pooled HR 1.51,1.001-2.280)。

临床怎么用

  • 根治性膀胱切除标本报告伴发原位癌时,应关注输尿管受累风险。
  • 对于器官局限患者,伴发原位癌提示需更密切随访无复发生存和癌症特异性生存。

局限性

  • 研究检索截止2017年10月,未纳入此后发表的研究。
  • 仅纳入采用多变量分析的研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the prognostic impact of concomitant carcinoma in situ in radical cystectomy specimens. MATERIALS AND METHODS: We performed a systematic review and meta-analysis using MEDLINE®, Scopus®, Web of Science™ and The Cochrane Library to identify eligible studies published until October 2017. Studies were eligible for analysis if they compared patients with concomitant carcinoma in situ in radical cystectomy specimens for bladder cancer to patients without concomitant carcinoma in situ to determine its value to prognosticate overall mortality, recurrence-free survival, cancer specific mortality and ureteral involvement using multivariable analysis. The protocol for this systematic review was registered in PROSPERO (Prospective Register of Systematic Reviews, CRD42018086539) and is available in full on the University of York website. RESULTS: Overall 23 studies published between 2006 and 2017 including a total of 20,647 patients were selected for the systematic review and meta-analysis. Concomitant carcinoma in situ was reported in 39.4% of radical cystectomy specimens. In studies analyzing all patients the presence of concomitant carcinoma in situ was not associated with overall mortality (pooled HR 0.92, 0.77-1.10), recurrence-free survival (pooled HR 1.06, 0.99-1.13) or cancer specific mortality (pooled HR 1.00, 0.93-1.07). It was associated with ureteral involvement (pooled OR 4.51, 2.59-7.84). On subanalysis of studies restricted to patients with organ confined bladder cancer at radical cystectomy concomitant carcinoma in situ was associated with worse recurrence-free survival (pooled HR 1.57, 1.12-2.21) and cancer specific mortality (pooled HR 1.51, 1.001-2.280). CONCLUSIONS: Concomitant carcinoma in situ is significantly associated with ureteral involvement in patients treated with radical cystectomy. In patients with organ confined disease concomitant carcinoma in situ in the radical cystectomy specimen is a prognosticator of recurrence-free survival and cancer specific mortality.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kimura S, Mari A, Foerster B, et al. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. J Urol. 2019. PMID: 30077559. doi:10.1016/j.juro.2018.05.162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。